NurExone (OTC-NRXBF) is a preclinical stage biotech company that is developing a breakthrough treatment for spinal cord injuries that has the potential to dramatically improve lives. The technology involved also has the potential to more efficiently get other treatments to the needed area. The company recently announced that its ExoPTEN spinal cord therapy has been granted Orphan Medicinal Product Designation by the European Medicines Agency.
